World’s leading pharmaceutical giants have estimated its market price to be worth more than 40 billion dollars a year. They have joined a race over a liquid biopsy test using a patient’s blood sample that could offer a new way to track several form of cancer The success in cancer treatment mostly depends on its early diagnosis and choosing an appropriate treatment regime based on the origin of cancer. Unfortunately, most of the times cancer is detected at the late stage, when it becomes unmanageable even with strong chemotherapy and painful surgical intervention.
Presently, diagnosis of cancer is achieved by taking out tissue sample from the affected organ and performing a biopsy of that sample. This is also an invasive technique and most of the patients who do not develop considerable symptoms, tend to avoid such tests. The development of simple, cost-effective, non-invasive methods…
